Articles On Cynata Therapeutics (ASX:CYP)

Cynata Therapeutics (ASX: CYP) revealed it is in “active discussions” with international pharmaceutical companies and other parties regarding using its Cymerus mesenchymal stem cell (MSC) platform to treat COVID-19 patients that develop sev...

As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the ‘c’ word. We’re talking of course about the coronavirus COVID-19 but sadly not another ‘c’ word: cure. Or not yet. Accor...

ShareCafeAll The Dope On Emerald Clinics’ Limp Debut Having been long on promises but short on deliverables, the ASX listed cannabis sector is taking an evolutionary step from growing the stuff to proving that pot is indeed the healing herb...

The Australian clinical-stage stem cell and regenerative medicine company is focused on the development of stem cell platform technology for commercial production with the help of pharmaceutical partner Fuji Film.

Cynata Therapeutics (CYP) has received a notice of allowance from the Israel Patent Office for a patent application for its Cymerus stem cell technology A notice of allowance is a good indicator that the applicant’s product will be issued...

Cynata Therapeutics (CYP) has released its December 2019 quarterly report, primarily outlining positive operations Highlights for the biotech company include planning multiple Phase 2 clinical trials and receiving a notice of allowance fro...

Cynata’s managing director Dr Ross Macdonald will present at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4.

With triple the number of sepsis cases in Australia, small cap biotech company Cynata Therapeutics (ASX:CYP) hopes to wage a new war on blood infections. Last Friday the world learned blood infections were on the rise, with researchers show...

In a preclinical study in a mouse model of CLI, treatment with Cymerus MSCs led to significantly higher blood flow in the ischaemic limb and protection against muscle damage, fibrosis and limb loss.

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

Cynata Therapeutics (CYP) has received approval from the U.K. Medicines and Healthcare products Regulatory Agency to begin the phase 2 trial of CYP-002 This product will be used in patients with reduced blood flow in their limbs The comp...

14 Jan 2020 - Cell therapeutics company Cyanata (ASX:CYP) has received the greenlight from British medical authority MHRA to begin the company’s Phase 2 clinical trial of its CYP-0…

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 136-odd small cap health stocks, 47 saw their share prices fall, 67 improved and 22 were flat. >> Scroll down for a table showing the performance of s...

The Cynata Therapeutics Ltd (ASX: CYP) share price was on form on Tuesday. The clinical-stage biotechnology company’s shares finished the day 5% higher at $1.20. This stretches its year to date gain to almost 15%. Why did the Cynata share...

Cynata Therapeutics (CYP) has received a research and development tax incentive of nearly $2 million for the 2018-2019 financial year This refund increases the company’s cash position which stood at $9.2 million at the end of the Septembe...

07 Jan 2020 - Biotechnology company Cynata Therapeutics (ASX:CYP) has received an almost $2 million R&D Tax Incentive Refund for the 2018/2019 financial year.

The Cynata Therapeutics Ltd (ASX: CYP) share price has jumped 9.8% after opening today, with CYP shares trading at $1.11 at the time of writing. Cynata shares had closed at $1.02 yesterday before opening at $1.10 this morning and moving hi...

Pre-clinical studies using Cynata Therapeutics’ (ASX: CYP) Cymerus mesenchymal stem cells in a sepsis model have achieved positive results. In a pre-clinical model of severe pneumonia-induced sepsis, Cynata’s Cymerus treatment had several p...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

The company is an Australian clinical-stage stem cell and regenerative medicine corporation focused on the development of therapies based on Cymerus – a therapeutic stem cell platform technology.

Health care system of Australia is considered as one of the best, globally, as it delivers safe and affordable health care solutions and services to the citizens. Health care sector in Australia comprises of medical service, medical insuran...

The Cynata Therapeutics Ltd (ASX: CYP) share price has come under pressure on Thursday. Its shares were down as much as 15% at one stage before rebounding slightly. Unfortunately, this sizeable decline has wiped out the majority of Cynata’...

Avecho Biotechnology (ASX:AVE), the company formerly known as Phosphagenics, announced that its Japanese partner is pulling support after three years of research. Avecho has a patented drug delivery system called targeted penetration matrix...

17 Oct 2019 - Biotech company Cynata Therapeutics (ASX:CYP) has decided to withdraw from acquisition discussions with Sumitomo Dainippon Pharma Co.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Strong gains among selected life science shares is fuelling optimism the sector may have further to run. Life sciences stocks are involved in things like biotech, genetics, pharmaceuticals and medical devices. In a low growth earnings envir...

Australian regenerative medicine company Cynata Therapeutics (ASX:CYP) has announced it has received the US$3 million relating to Fujifilm exercising its license option in graft-versus-host disease.

Do you know that on this day in 1970 the great American rock guitarist, singer, and songwriter Jimi Hendrix passed away. James Marshall 'Jimi' Hendrix’s mainstream career lasted only four years, but he is widely regarded as one of the most...

Australian regenerative medicine company Cynata Therapeutics (ASX:CYP) has announced Fujifilm has exercised its license option in graft-versus-host disease.

On Stockhead today, the gold M&A just keeps rolling with Azumah the latest takeover target, SRJ reveals why it thinks Oz is a good place for it to list and the industry that billionaire investor Stephen Schwarzman sees as having ‘Amazon...

Cynata Therapeutics Ltd [ASX:CYP] reported a massive win late last night. Their Japanese benefactor, Fujifilm, is going to license their CYP-001 treatment. The post Fujifilm Takes the Plunge on Cynata appeared first on Money Morning Austra...

Following a successful phase one clinical trial, FUJIFILM Corporation (Fujifilm) has exercised its option to commercialise Cynata Therapeutics’ (ASX: CYP) mesenchymal stem cell product which can treat and prevent graft-versus-host disease i...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Shares in biotech Orthocell (ASX:OCC) are on the move again today after the company reported further positive results for its CelGro technology. Patients who completed the company’s CelGro tendon regeneration trial reported they had regaine...

04 Sep 2019 - Clinical-stage biotechnology company Cynata Therapeutics (ASX:CYP) is excited to have a scientific paper published on the efficacy of Cymerus MSCs in a preclinical mo…

Pharmaxis, one of last year’s biggest small cap reporting season winners, has tumbled 412 per cent into the red as its fortunes fluctuate on the anti-inflammatory drug it sold to German pharma giant Boehringer Ingelheim four years ago. Afte...

The Credible Labs Inc (ASX: CRD) share price looks set to storm higher this morning after the San Francisco-based consumer finance marketplace operator announced that it has entered into a definitive merger agreement with a subsidiary of F...

Japanese company Sumitomo Dainippon Pharma has moved to acquire Australian cell therapy company Cynata Therapeutics (ASX:CYP).

Healthcare being a large industry in Australia is a significant contributor to the country’s economy. The below-mentioned ASX listed healthcare stocks have been performing well over the past few months, plus have made strong operational pro...

Sponsored Content Sumitomo Dainippon Pharma, a $10 billion Japanese pharma company listed on the Tokyo Stock Exchange, has lobbed a $204 million takeover bid for Cynata Therapeutics (ASX:CYP). At a Glance Cynata has revealed it received a t...

The S&P/ASX 200 index has charged higher on Friday thanks largely to strong gains in the banking sector. In afternoon trade the benchmark index is up 0.7% to 6,697.5 points. Four shares that have climbed more than most today are listed...

Melbourne's Cynata Therapeutics says it doesn't believe a $202 million takeover offer it disclosed on Friday explains why its shares rose recently.

ASX shares at the smaller end of the market are outperforming along with the Australian dollar as the global investors up their bets that the US Federal Reserve will make its biggest ever interest rate cut in over 10 years. The S&P/ASX...

Stem cell manufacturer Cynata Therapeutics (ASX: CYP) has announced this morning it has received an acquisition proposal. Japanese pharmaceutical company Sumitomo Dainippon Pharma has proposed to acquire the company for $2 per share (which...

The Cynata Therapeutics Ltd (ASX: CYP) share price has been one of the best performers on the local market in morning trade. At the time of writing the clinical-stage stem cell and regenerative medicine company’s shares are up 15.5% to $1....

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Special Report: Stem cells still have somewhat of a bad rep, as news headlines either repeat the embryo origin story or recount shills promising them as a cure-all for everything from ADHD to Alzheimer’s. But beneath those headlines is a fl...